journal article·2026-02Open access

Biomimetic nanomaterial-based strategies for spinal cord injury repair

Rui-Lian Chen, Lu Jiang, Hai-Bo Teng, Jin-Long Yang, Wen-Bo He, Yang Zhang, Qing-qing Ren, Hong-Xu Chen, Rang-rang Fan, Jian-Guo Xu

Nano Today· Volume 67

Abstract

Spinal cord injury (SCI) poses significant clinical challenges marked by profound functional impairments and limited clinical interventions due to its complex pathological microenvironment and limited intrinsic regenerative capacity. This review systematically explores the pathophysiology of SCI, emphasizing key therapeutic targets in neuroprotection, axon regeneration, and immunomodulation. We innovatively propose a functional classification framework to categorize synthetic nanomaterials into (1) targeted drug delivery systems, (2) nanoparticle-hydrogel hybrid systems and (3) stimuli-responsive functional nanoparticles, effectively resolving overlaps in traditional classifications. Furthermore, biogenic nanomaterials—including exosomes, cell membrane-coated systems, and decellularized extracellular matrix (ECM) scaffolds—are highlighted for their innate biocompatibility, immune evasion, and bioactivity. These biogenic nanomaterials synergize with advanced technologies such as genetic engineering and combinatorial therapies to enhance neural repair. Particularly, we provide the first systematic comparison of microstructural differences in decellularized scaffolds derived from diverse tissues (e.g., spinal cord, optic nerve, sciatic nerve) and their mechanisms in guiding axonal regeneration. Despite promising preclinical outcomes, challenges such as standardization, scalable production and long-term biosafety remain in the gap between experimental models and clinical applications. Future directions focus on dynamic responsiveness, multifunctional combinatorial designs and integration with regenerative medicine paradigms to achieve functional recovery in SCI management.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: Extracellular vesicles in disease · Nerve injury and regeneration · Spinal Cord Injury Research

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

References (100+)

Show source-provided references
1. Direct cost of illness for spinal cord injury: a systematic review10.1177/21925682211031190 ↗
2. The influence of time from injury to surgery on motor recovery and length of hospital stay in acute traumatic spinal cord injury: an observational Canadian cohort study10.1089/neu.2014.3632 ↗
3. Clinical neurorestorative therapeutic guidelines for spinal cord injury (IANR/CANR version 2019)
4. Local delivery strategies to restore immune homeostasis in the context of inflammation10.1016/j.addr.2021.113971 ↗
5. Robust and multifunctional nanoparticles assembled from natural polyphenols and metformin for efficient spinal cord regeneration10.1021/acsnano.3c06991 ↗
6. Multifunctional hydrogel modulates the immune microenvironment to improve allogeneic spinal cord tissue survival for complete spinal cord injury repair10.1016/j.actbio.2022.11.015 ↗
7. Spinal cord injury: molecular mechanisms and therapeutic interventions
8. Three-dimensional bioprinting sodium alginate/gelatin scaffold combined with neural stem cells and oligodendrocytes markedly promoting nerve regeneration after spinal cord injury10.1093/rb/rbac038 ↗
9. Crosstalk between cell death and spinal cord injury: neurology and therapy10.1007/s12035-024-04188-3 ↗
10. Resident immune responses to spinal cord injury: role of astrocytes and microglia10.4103/1673-5374.389630 ↗
11. The influence of pathological extracellular matrix on the biological properties of stem cells: possible hints for cell transplantation therapies in spinal cord injury10.3390/ijms26093969 ↗
12. Nanomedicine innovations in spinal cord injury management: bridging the gap10.1016/j.envres.2023.116563 ↗
13. Nanotechnology for the treatment of spinal cord injury10.1089/ten.teb.2020.0188 ↗
14. Harnessing nanotechnology for cancer treatment10.3389/fbioe.2024.1514890 ↗
15. Biosynthesis of gold nanoparticles, characterization and their loading with zonisamide as a novel drug delivery system for the treatment of acute spinal cord injury10.1016/j.jphotobiol.2018.11.011 ↗
16. TAT-modified tetramethylpyrazine-loaded nanoparticles for targeted treatment of spinal cord injury10.1016/j.jconrel.2021.05.016 ↗
17. Selective modulation of A1 astrocytes by drug-loaded nano-structured gel in spinal cord injury10.1021/acsnano.9b05579 ↗
18. Fluorescent phosphorus dendrimer as a spectral nanosensor for macrophage polarization and fate tracking in spinal cord injury10.1002/mabi.201500150 ↗
19. Effective modulation of CNS inhibitory microenvironment using bioinspired hybrid-nanoscaffold-based therapeutic interventions
20. Saijilafu, GDNF-Loaded polydopamine nanoparticles-based anisotropic scaffolds promote spinal cord repair by modulating inhibitory microenvironment10.1002/adhm.202202377 ↗
21. Emerging approaches of neural regeneration using physical stimulations solely or coupled with smart piezoelectric nano-biomaterials10.1016/j.ejpb.2022.02.016 ↗
22. Biomimetic nanomaterials based on peptide in situ self-assembly for immunotherapy applications
23. Traumatic spinal cord injury10.1038/nrdp.2017.18 ↗
24. The role of microglia in modulating neuroinflammation after spinal cord injury10.3390/ijms22189706 ↗
25. Chondroitin sulphate proteoglycans in the central nervous system: changes and synthesis after injury10.1042/bst0310335 ↗
26. Microglia and macrophages promote corralling, wound compaction and recovery after spinal cord injury via Plexin-B210.1038/s41593-020-0597-7 ↗
27. Astrocyte barriers to neurotoxic inflammation10.1038/nrn3898 ↗
28. Central nervous system regenerative failure: role of oligodendrocytes, astrocytes, and microglia10.1101/cshperspect.a020602 ↗
29. Neurotoxic reactive astrocytes are induced by activated microglia10.1038/nature21029 ↗
30. The glial scar and central nervous system repair10.1016/S0361-9230(99)00072-6 ↗
31. Traumatic spinal cord injury—repair and regeneration10.1093/neuros/nyw080 ↗
32. Inflammation after spinal cord injury: a review of the critical timeline of signaling cues and cellular infiltration10.1186/s12974-021-02337-2 ↗
33. Advances in novel biomaterial-based strategies for spinal cord injury treatment10.1021/acs.molpharmaceut.3c01104 ↗
34. Temporal and spatial cellular and molecular pathological alterations with single-cell resolution in the adult spinal cord after injury
35. Spinal cord injury: pathophysiology, multimolecular interactions, and underlying recovery mechanisms10.3390/ijms21207533 ↗
36. Advanced approaches to regenerate spinal cord injury: the development of cell and tissue engineering therapy and combinational treatments10.1016/j.biopha.2021.112529 ↗
37. Targeting apoptosis and autophagy following spinal cord injury: therapeutic approaches to polyphenols and candidate phytochemicals10.1016/j.phrs.2020.105069 ↗
38. Targeted therapy of spinal cord injury: inhibition of apoptosis is a promising therapeutic strategy10.1007/s12035-023-03814-w ↗
39. Recent advance in bioactive hydrogels for repairing spinal cord injury: material design, biofunctional regulation, and applications10.1186/s12951-023-01996-y ↗
40. Advances in secondary spinal cord injury: role of apoptosis10.1097/00007632-200007150-00022 ↗
41. Molecular biology of cervical myelopathy and spinal cord injury: role of oligodendrocyte apoptosis10.1016/S1529-9430(03)00117-7 ↗
42. Neuronal and glial apoptosis after traumatic spinal cord injury10.1523/JNEUROSCI.17-14-05395.1997 ↗
43. Apoptosis after traumatic human spinal cord injury10.3171/jns.1998.89.6.0911 ↗
44. Review of current evidence for apoptosis after spinal cord injury10.1089/neu.2000.17.915 ↗
45. Inflammation & apoptosis in spinal cord injury
46. ROS: executioner of regulating cell death in spinal cord injury10.3389/fimmu.2024.1330678 ↗
47. Cellular and subcellular oxidative stress parameters following severe spinal cord injury10.1016/j.redox.2015.12.011 ↗
48. Reactive oxygen species-scavenging biomaterials for neural regenerative medicine10.1039/D4BM01221F ↗
49. TNF-induced necroptosis and PARP-1-mediated necrosis represent distinct routes to programmed necrotic cell death10.1007/s00018-013-1381-6 ↗
50. Antioxidant MnO2 nanozymes-encapsulated hydrogel synergistically regulate the spinal ROS microenvironment and promote spinal cord repair10.1016/j.cej.2023.147148 ↗
51. Hierarchical gelatin-derived hydrogel film with reactive oxygen species scavenging properties for spinal cord injury repair10.1016/j.cej.2024.158134 ↗
52. Calcineurin-mediated BAD dephosphorylation activates the caspase-3 apoptotic cascade in traumatic spinal cord injury10.1523/JNEUROSCI.20-19-07246.2000 ↗
53. The role of excitotoxicity in secondary mechanisms of spinal cord injury: a review with an emphasis on the implications for white matter degeneration10.1089/0897715041269641 ↗
54. CXCR4-activated astrocyte glutamate release via TNF-alpha: amplification by microglia triggers neurotoxicity10.1038/89490 ↗
55. HSPA1A ameliorated spinal cord injury in rats by inhibiting apoptosis to exert neuroprotective effects10.1016/j.expneurol.2022.114301 ↗
56. Increased production of tumor necrosis factor-alpha induces apoptosis after traumatic spinal cord injury in rats10.1089/08977150360547116 ↗
57. Progranulin deficiency exacerbates spinal cord injury by promoting neuroinflammation and cell apoptosis in mice10.1186/s12974-019-1630-1 ↗
58. Fas/FasL-mediated apoptosis and inflammation are key features of acute human spinal cord injury: implications for translational, clinical application10.1007/s00401-011-0882-3 ↗
59. Ferroptosis: an iron-dependent form of nonapoptotic cell death10.1016/j.cell.2012.03.042 ↗
60. Sodium selenite promotes neurological function recovery after spinal cord injury by inhibiting ferroptosis10.4103/1673-5374.314322 ↗
61. Ferroptosis inhibitor improves outcome after early and delayed treatment in mild spinal cord injury10.1007/s00401-024-02758-2 ↗
62. Mesenchymal stem cell attenuates spinal cord injury by inhibiting mitochondrial quality control-associated neuronal ferroptosis10.1016/j.redox.2023.102871 ↗
63. Ferroptosis: a critical player and potential therapeutic target in traumatic brain injury and spinal cord injury10.4103/1673-5374.350187 ↗
64. Sustained induction of heme oxygenase-1 in the traumatized spinal cord10.1006/exnr.2000.7520 ↗
65. Quantitative proteomics identifies NCOA4 as the cargo receptor mediating ferritinophagy10.1038/nature13148 ↗
66. The chemical basis of ferroptosis10.1038/s41589-019-0408-1 ↗
67. Ferroptosis: mechanisms, biology and role in disease10.1038/s41580-020-00324-8 ↗
68. Loss of cardiac ferritin H facilitates cardiomyopathy via Slc7a11-mediated ferroptosis10.1161/CIRCRESAHA.120.316509 ↗
69. Selenium utilization by GPX4 is required to prevent hydroperoxide-induced ferroptosis10.1016/j.cell.2017.11.048 ↗
70. Regulation of ferroptotic cancer cell death by GPX410.1016/j.cell.2013.12.010 ↗
71. ACSL4 dictates ferroptosis sensitivity by shaping cellular lipid composition10.1038/nchembio.2239 ↗
72. Ferroptosis and necroinflammation, a yet poorly explored link10.1038/s41418-018-0173-9 ↗
73. TNF and increased intracellular iron alter macrophage polarization to a detrimental M1 phenotype in the injured spinal cord10.1016/j.neuron.2014.07.027 ↗
74. Deferoxamine promotes recovery of traumatic spinal cord injury by inhibiting ferroptosis10.4103/1673-5374.245480 ↗
75. On the mechanism of cytoprotection by ferrostatin-1 and liproxstatin-1 and the role of lipid peroxidation in ferroptotic cell death10.1021/acscentsci.7b00028 ↗
76. Non-canonical glutamate-cysteine ligase activity protects against ferroptosis10.1016/j.cmet.2020.12.007 ↗
77. Differences in cytokine gene expression profile between acute and secondary injury in adult rat spinal cord10.1016/S0014-4886(03)00361-3 ↗
78. Identification of two distinct macrophage subsets with divergent effects causing either neurotoxicity or regeneration in the injured mouse spinal cord10.1523/JNEUROSCI.3257-09.2009 ↗
79. Modulating the immune response in spinal cord injury10.1080/14737175.2016.1207532 ↗
80. Update on the pathophysiology and pathology of acute spinal cord injury10.1111/j.1750-3639.1995.tb00619.x ↗
81. MicroRNA regulatory pattern in spinal cord ischemia-reperfusion injury10.4103/1673-5374.280323 ↗
82. Macrophage phagocytosis after spinal cord injury: when friends become foes10.1093/brain/awab250 ↗
83. Delivery of pOXR1 through an injectable liposomal nanoparticle enhances spinal cord injury regeneration by alleviating oxidative stress
84. The biology of regeneration failure and success after spinal cord injury10.1152/physrev.00017.2017 ↗
85. Reactive astrocytes inhibit the survival and differentiation of oligodendrocyte precursor cells by secreted TNF-α10.1089/neu.2010.1597 ↗
86. Function of microglia and macrophages in secondary damage after spinal cord injury10.4103/1673-5374.143423 ↗
87. Matrix metalloproteinases limit functional recovery after spinal cord injury by modulation of early vascular events10.1523/JNEUROSCI.22-17-07526.2002 ↗
88. Progression in translational research on spinal cord injury based on microenvironment imbalance10.1038/s41413-022-00199-9 ↗
89. Interaction of reactive astrocytes with type I collagen induces astrocytic scar formation through the integrin-N-cadherin pathway after spinal cord injury10.1038/nm.4354 ↗
90. Aryl hydrocarbon receptor modulates stroke-induced astrogliosis and neurogenesis in the adult mouse brain10.1186/s12974-019-1572-7 ↗
91. Microglial control of astrocytes in response to microbial metabolites10.1038/s41586-018-0119-x ↗
92. Neuroimmunological therapies for treating spinal cord injury: evidence and future perspectives10.1016/j.expneurol.2021.113704 ↗
93. Tissue engineering approaches to modulate the inflammatory milieu following spinal cord injury10.1159/000446646 ↗
94. The role of immune cells and associated immunological factors in the immune response to spinal cord injury10.3389/fimmu.2022.1070540 ↗
95. Microglia: new roles for the synaptic stripper10.1016/j.neuron.2012.12.023 ↗
96. Safety challenges and application strategies for the use of dendrimers in medicine10.3390/pharmaceutics14061292 ↗
97. Deletion of the fractalkine receptor, CX3CR1, improves endogenous repair, axon sprouting, and synaptogenesis after spinal cord injury in mice10.1523/JNEUROSCI.2841-16.2017 ↗
98. Divergent transcriptional regulation of astrocyte reactivity across disorders10.1038/s41586-022-04739-5 ↗
99. Astrocyte-derived Wnt growth factors are required for endothelial blood-brain barrier maintenance10.1016/j.pneurobio.2020.101937 ↗
100. Reactive astrogliosis after spinal cord injury—beneficial and detrimental effects10.1007/s12035-012-8287-4 ↗